Revelation Biosciences grants restricted stock awards to CEO and CFO

Revelation Biosciences, Inc. (REVB) has granted restricted stock awards to its CEO James Rolke and CFO Chester Zygmont, III. The awards, under the company's 2021 Equity Incentive Plan, were approved by the Compensation Committee. Mr. Rolke received 208,076 shares, while Mr. Zygmont got 208,073 shares. These awards are subject to four equal tranches of vesting over time, contingent on continued service with the company.

They become fully vested before a Change in Control, unless stated otherwise in an individual agreement. In the event of death, termination without cause, or resignation for good reason, the awards are fully vested and nonforfeitable. Unvested shares are forfeited upon termination for other reasons. This move is part of Revelation Biosciences' strategy to strengthen its research and development initiatives, especially as the company prepares for a Phase 2/3 clinical trial of its Gemini treatment candidate.

The addition of experienced nephrologists and critical care physicians to its Acute Kidney Injury Advisory Board will guide the clinical strategy and monitor the trial's progress.